Barclays upgraded shares of Sagimet Biosciences (NASDAQ:SGMT – Free Report) to a hold rating in a report published on Tuesday,Zacks.com reports. Zacks Research cut Sagimet Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 12th. Get Sagimet Biosciences alerts:View Our Latest Analysis on Sagimet BiosciencesSagimet Biosciences Trading Down 8.3%Shares of SGMT stock traded down $0.49 on Tuesday, reaching $5.37. As a group, sell-side analysts predict that Sagimet Biosciences will post -1.6 earnings per share for the current fiscal year. Featured StoriesReceive News & Ratings for Sagimet Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sagimet Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.